Mode
Text Size
Log in / Sign up
N/A Completed N=24 Treatment

Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms

Source: ClinicalTrials.gov NCT02611206 ↗
Enrolled (actual)
24
Serious AEs
14.3%
Results posted
May 2023
Primary outcomePrimary: Change in Score on Child Depression Rating Scale - Revised (CDRS-R) — 12.33; 1.33; 22.13 score on a scale

Summary

This study will be an open-label 6-week (30 session) trial of active repetitive transcranial magnetic stimulation (rTMS) using a fixed frequency (10 Hz) but varying stimulation intensities using a 3+3 study design for safety and tolerability amongst adolescents. This means that we will only enroll 3 participants at a time and give them rTMS at the stimulation intensity energy of 80% of motor threshold (MT). If all three participants complete the 6 weeks of treatment with no major safety events (i.e. seizure), we will increase the energy for the next 3 participants by 20%. If 1 of the 3 participants has a major safety event, we will enroll 3 more patients at the SAME energy. We will proceed in this manner, increasing by 20% after 3 subjects safely complete treatment at that energy, to a maximum energy of 120% of motor threshold. If 2 participants in each intensity level cohort experience a major safety event, we will discontinue running subjects at that energy level. If this happens at our initial energy level of 80% of MT, we will stop the study. If we reach 2 events in any of the higher energy cohorts, we will return to the previous energy level and complete the remainder of the subjects at that energy level.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Score on Child Depression Rating Scale - Revised (CDRS-R)
12.33; 1.33; 22.13
SECONDARY
Change in Score Beck Depression Inventory (BDI-II)
12.33; 7.33; 10.38
SECONDARY
Change is Score Columbia Suicide Severity Rating Scale (C-SSRS)
4.33; 0.33; 3.38
SECONDARY
Change in Score Temporal Experience of Pleasure Scale (TEPS)
-3; 2.5; 0.75
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: General Depression
7.67; 1.5; 17.67
SECONDARY
Change in Score Young Mania Rating Scale
-0.67; 3; -1.14
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Dysphoria
5.67; 5.5; 8.83
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Lassitude
2.33; 1; 6.67
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Insomnia
1; -3.5; 6.33
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Suicidality
0.67; 2; 4.17
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Appetite Loss
0; -4; 1.33
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Appetite Gain
1; 0.5; -0.33
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Ill Temper
0.67; 4.5; 1.17
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Well Being
2.67; 1; 3.17
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Social Anxiety
2.67; 1; 3.17
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Panic
2.67; -0.5; 1.17
SECONDARY
Change in Score Inventory of Depression and Anxiety Symptoms (IDAS) Subscale: Traumatic Intrusions
0.33; 0.5; -1.5

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Major Depressive Disorder (MDD)
  • A CDRS-R score of >40
  • Experiencing a current MDD episode with a duration of ≥ 4 weeks and ≤3 years
  • Resistance to treatment, defined by failure to respond adequately to at least one antidepressant treatment, defined by ATR level 1-4 in current episode
  • Both child and parent/guardian are English speaking
  • Female participants who are sexually active during the course of the study must use a form of birth control for the duration of the study

Exclusion Criteria

  • Any subject with a clinically defined neurological disorder or insult including, but not limited to, a condition likely to increase the risk of seizure; such as, space occupying brain lesion; any history of seizure; history of cerebrovascular accident; transient ischemic attack within two years; cerebral aneurysm; dementia; brain surgery; history or stroke or family history of epilepsy
  • Any subject with an increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure or history of significant head trauma with loss of consciousness for ≥ 5 minutes
  • Positive responses to any question on the Transcranial Magnetic Stimulation Adult Safety Screening Questionnaire (TASS)
  • Subjects with cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute unstable cardiac diseases
  • Subjects with conductive, ferromagnetic, or other magnetic-sensitive metals implanted in the head within 30 cm of the treatment coil excluding the mouth that cannot safely be removed should be excluded. Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes
  • Subjects with active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, and vagus nerve stimulators
  • Inability to locate and quantify a motor threshold as defined in the protocol
  • History of treatment with ECT or TMS therapy for any disorders
  • Participation in any investigational drug trial within 4 weeks of the baseline visit
  • Pregnancy
  • IQ < 80
  • Clinically significant laboratory abnormality or medical condition, that in the opinion of the investigator would hinder the subject in completing the procedures required by the study
  • Suicide attempt within the previous 6 months that required medical treatment or ≥2 attempts in the past 12 months, or has a clear plan for suicide and states that s/he cannot guarantee that s/he will inform a family member or call his/her psychiatrist or the investigator if the impulse to implement the plan becomes substantial during the study; or, in the investigator's opinion, is likely to attempt suicide within the next 6 months
  • Unstable psychotherapy (therapy must be for at least 3 months prior to entry into the study, with no anticipation of change in the frequency or treatment focus of the therapeutic sessions over the duration of the study)
  • A diagnosis of substance use disorder, Schizophrenia, Bipolar Disorder, or Autism
  • Refusal to cooperate with study procedures
  • Recent change in dose of antidepressant medication (within 6 weeks prior to initial evaluation). This includes all antidepressants and any adjunctive psychotropic medications that are being used to address problems related to mood or anxiety (e.g. antipsychotic medications, mood stabilizers.) This does not include stimulant medications that are being used to treat Attention Deficit Hyperactivity Disorder (ADHD).**
  • Current treatment with Bupropion at a dose greater than 150mg per day.
  • Current treatment with a stimulant medication as an adjunct medication for depression.***
  • Current treatment with a stimulant medication for ADHD above FDA recommended dosages.***

(*) If the participant has an insufficient number of trials in the current episode, then the participant must also have failed ≥1 and ≤4 trials in a previous episode. Subjects who have been unable to complete an

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02611206). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search